Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. - Ison MG; Papi A; Athan E; Feldman RG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Cuadripani S; Deraedt Q; et al. (The Lancet. Respiratory medicine, 2025)